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Bilastine is a new second generation H1-antihistamine recently approved for the symptomatic treatment of allergic
rhinitis (AR) and chronic urticaria (CU). Bilastine epitomizes the evolution of research on antihistamines concerning
both efficacy and safety. In AR treatment, a number of large controlled clinical trials documented its efficacy, as
assessed by improvement of all nasal and ocular symptoms and quality of life. These outcomes show that bilastine
meets current EAACI/ARIA criteria for medications used in the treatment of AR. Also in CU, the review of the
literature indicates that once-daily treatment with bilastine 20 mg was effective in managing symptoms and
improving patient’s quality of life. Concerning safety and tolerability, the profile of bilastine is very similar to
placebo and in particular the adverse effects on central nervous system are insignificant. The balance of efficacy
and safety of bilastine is particularly helpful when dosages higher than standard are needed to control the
symptoms, as frequently occurs in patients with urticaria, in whom antihistamines doses up to four times the
standard dose may be administered.
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Bilastine is a new second generation H1-antihistamine
recently approved for the symptomatic treatment of allergic
rhinitis (AR) and chronic urticaria (CU) in patients older
than 12 years of age. AR and urticaria are very common
clinical conditions that represent one of the most frequent
reasons for a patient to visit their general practitioner or
allergist. In the European countries 18% of population is
suffering from AR [1] and in the United States AR affects a
range of 10-30% of adults and up to 40% of children [2].
For urticaria, the life-time prevalence is approximately 20%
for acute urticaria and 1.8% for CU [3]. These two clinical
entities, though they have different and distinct characteris-
tics, both cause a significant impairment of quality of life
(QoL) and loss of productivity [4-6]. AR and urticaria re-
spond to antihistamine treatment and current international
guidelines recommend nonsedating second generation
antihistamines as first line treatment for both [3,7,8].
The role of histamine in allergic inflammation is un-
equivocal. It exerts its biological effects acting on four
distinct receptors, but among them the H1-receptor
plays the most important role in allergic diseases. H1-* Correspondence: erminia.ridolo@unipr.it
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unless otherwise stated.antihistamines can control allergic inflammation by dir-
ectly interfering with histamine action at H1 receptors
[9]. Based on their ability to cross the blood–brain
barrier, H1-antihistamines are classified into 2 groups:
the first generation antihistamines that bind the H1-
receptors on neurons in the central nervous system,
causing sedation and impaired mental status, and the
second-generation antihistamines (including bilastine) that
usually cannot cross the blood–brain barrier and thus
have fewer sedative effects. The long duration of action,
efficacy, low-sedation impact and low-performance im-
pairment of second generation antihistamines, and par-
ticularly of bilastine, make it a potentially attractive
therapeutic option for allergists.
This review focuses on the clinical characteristics of
bilastine and the evidence of its efficacy in the treatment
of AR and urticaria.Review
Pharmacodynamic and pharmacokinetic properties
From a molecular point of view, bilastine is 2-[4-(2-(4-
(1-(2- ethoxyethyl)-1Hbenzimidazol-2-yl) piperidin-1-yl)
ethyl) phenyl]-2-methyl propionic acid. It belongs to pi-
peridine derivatives and is not structurally derived from
any other currently available antihistamines. Bilastine ex-
erts a potent and specific H1-antihistamine activity.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ridolo et al. Clinical and Molecular Allergy  (2015) 13:1 Page 2 of 6Bilastine is an H1 receptor inverse agonist, like other
antihistamines already available. Preclinical in vitro studies
showed that bilastine has high specificity for H1-receptors
while has negligible affinity for 30 other receptors (sero-
tonin, bradykinin, leukotriene-D4, muscarinic M3-receptors,
α1-adrenoceptors, β2-adrenoceptors, and H2- and H3-
histamine receptors) [10]. The affinity for the H1 receptor
is 3 and 6 times higher than for cetirizine and fexofena-
dine, respectively. The results of in vivo preclinical studies
confirmed those obtained from in vitro experiments, as
in rats bilastine has demonstrated to reduce histamine-
stimulated smooth muscular contraction, bronchospasms,
endothelial permeability, and microvascular extravasation,
providing evidence to possess antiallergic properties, with
similar potency to cetirizine and superior potency to fexo-
fenadine [11].
In vitro data have shown that bilastine also exerts anti-
inflammatory activity by inhibiting the release of histamine,
IL-4 and tumor necrosis factor (TNF)-α from human mast
cells and granulocytes [12].
The drug is rapidly absorbed after oral administration
with a time to maximum plasma concentration of around
1 hour following administration [13]. The mean value of
bilastine oral bioavailability was found to be about 60%
[14]. The maximum plasma concentration (220 ng/mL)
of bilastine 20 mg was detected 1.3 hours after administra-
tion, the half time was 14.5 hours, and plasma protein
binding was 84–90% [13,14]. Bilastine does not undergo
any significant hepatic metabolism and approximately 95%
is excreted intact in faeces (67%) or in urine (33%); bilas-
tine is a substrate for P-glycoprotein which limits its pas-
sage across the blood–brain barrier [15], and not clinically
relevant interactions have been reported to date. The
mean elimination half-life calculated in healthy volun-
teers was 14.5 h and the apparent total plasma clearance is
18.1 L/h [16,17]. Bilastine is not a substrate of CYP450
family [18].
Efficacy of bilastine
Wheal and flare inhibition
A phase 1, double-blind, randomised, placebo-controlled,
single oral dose, cross-over study compared the antihista-
minic effects of bilastine, cetirizine and placebo against
histamine-induced wheal and flare responses, over periods
of 24 h, in 21 healthy male volunteers [19]. In that trial,
volunteers were randomised to receive single oral doses of
bilastine 20 or 50 mg, cetirizine 10 mg or placebo before
provocation of wheal and flare responses to 100 mg/ml
histamine by skin prick 1.5, 4, 8, 12 and 24 h later. The
authors found no significant differences between overall
inhibitions of wheal or flare by bilastine 20 mg and
cetirizine10 mg but bilastine was faster in onset of ac-
tion than cetirizine, inhibition of wheal and flare at 1.5 h
being 89 ± 3 versus 44 ± 14% (P = 0.011) and 85 ± 4 versus45 ± 14% (P = 0.016), respectively. At 1.5 h, both wheals
and flares were inhibited by 70% in 11/12 volunteers tak-
ing bilastine and 3/11 taking cetirizine (P = 0.003). There
were no significant differences between the drugs at later
times.
Bilastine efficacy in allergic rhinitis
Efficacy of bilastine was well recognized in both seasonal
and perennial allergic rhinitis. The Vienna Challenge
Chamber is an established standardized method for the
controlled exposure of patients to defined allergens, that is
used to make comparisons between different antihistamines
[20,21]. Using this method, a double blind, randomized,
placebo controlled, balanced four-treatment, four-period
crossover phase II study was conducted in patients suffer-
ing from seasonal AR (SAR) in order to compare the effi-
cacy of bilastine, cetirizine and fexofenadine to relieve
symptoms [22]. The study was conducted in adult patients
with confirmed allergy to grass pollen, outside the pollen
season while they were asymptomatic. Total Nasal Symp-
toms Score (TNSS) was used to compare the effect of a
single dose of bilastine 20 mg, cetirizine 10 mg, fexofena-
dine 120 mg and placebo administered two hours after the
start of the challenge. During the first four hours after
administration, all treatment were significantly more ef-
fective than placebo in reducing TNSS (p < 0.001), without
significant difference between the three antihistamines.
Moreover, bilastine at 20 mg was as effective as cetirizine
10 mg and fexofenadine 120 mg in terms of onset of ac-
tion and in reducing eye symptoms 1 h after the intake.
Bilastine was still effective 26 hours after the intake,
confirming the prolonged duration of action.
The efficacy of bilastine in patients with SAR has also
been evaluated in two double-blind, placebo-controlled
studies, with the same design, evaluating parameters for
efficacy and safety, including assessment of QoL in the
first one, comparing once daily bilastine 20 mg with pla-
cebo, desloratadine 5 mg and cetirizine 10 mg over two
weeks [23,24]. Details of the two studies are provided in
table 1. These two studies enrolled a total of 1404 pa-
tients, aged between 12 and 70 years, with documented
SAR due to pollen allergens. In both studies primary out-
come measure of TSS was significantly reduced in the
bilastine group significantly more than in the placebo group
and to a similar extent as in the active comparator group
(table 1). Also, bilastine improved QoL, measured by rhino-
conjunctivitis quality of life questionnaire (RQLQ), to a
similar extent than desloratadine; bilastine 20 mg sig-
nificantly improved total RQLQ score and most RQLQ
single domains respect to placebo.
A multicenter, randomized, placebo-controlled, double-
blind, parallel-group study was conducted in 650 patients
with symptomatic persistent AR (PAR) [25]. The authors
found no significant differences in efficacy outcomes
Table 1 Double blind randomized trials in seasonal AR
Study Patients N. Duration Treatment Efficacy Safety vs active comparator
Kuna P et al. [24] 683 14 days Bilastine 20 mg
Cetirizine 10 mg
Placebo
The mean TSS-AUC0_14 days (score_day)
was reduced in bilastine and cetirizine
groups to a similar and significantly
greater extent, compared with placebo
(P < 0.001). Bilastine and cetirizine were
comparable and significantly superior
to placebo for all secondary outcomes
Significantly fewer patients in the
bilastine-treated group experienced
somnolence (P < 0.001) and fatigue
(P = 0.02) than patients in the
cetirizine-treated group.
Bachert C et al. [23] 721 14 days Bilastine 20 mg
Desloratadine 5
mg Placebo
The AUC of TSS was decreased to a
significantly greater extent in the
bilastine group compared with
placebo group (P < 0.001). Total RQLQ
score was significantly reduced from
baseline by a value of 1.6 (1.2; 1.8–1.4)
in the bilastine treated group compared
with a value of 1.3 (1.3; 1.5–1.1) in the
placebo-treated group (P < 0.005)
Safety profile of bilastine and
desloratadine were comparable
to placebo.
TSS-AUC0_14: area under the curve (AUC) of the reflective total symptoms score (TSS) from day 0 (D0) today 14; RQLQ: rhinoconjunctivitis quality of
life questionnaire.
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population, over 4 weeks of treatment, but in the post-hoc
analysis bilastine 20 mg was more effective than placebo
and as effective as cetirizine 10 mg the population of
patients from Europe and Argentina, while the difference
remained not statistically significant in patients from
South Africa. The lack of efficacy through the whole
group was likely to be due to the group great variability
of symptom scores reported in different countries, par-
ticularly in South Africa [26].
Davila et al. and Bartra et al. analyzed the data about
the effect of bilastine upon nasal obstruction and ocular
symptoms from 7 phase II and phase III 2–4 weeks dur-
ation clinical trials [27,28]. Mean change from baseline in
nasal obstruction symptoms score after two weeks of treat-
ment was −0.66 with bilastine 20 mg and −0.57 with pla-
cebo (p < 0.001), active comparators (cetirizine 10 mg and
desloratadine 5 mg) induced a reduction of −0.67 points
(p < 0.001 vs placebo; not statistically different vs bilastine)
[27]. Similarly, bilastine was more effective in ocular symp-
toms relief than placebo and as effective as active compara-
tors [28].
Bilastine efficacy in urticaria
A multi-centre, double-blind, randomized, placebo-
controlled study compared the efficacy and safety of
bilastine 20 mg vs levocetirizine 5 mg for the treatment of
chronic idiopathic urticaria in 525 adult patients [29]. The
TSS was reduced progressively by all treatments from
baseline over a period of 28 days treatment, with signifi-
cant differences noted between bilastine 20 mg and levo-
cetirizine 5 mg-treated groups vs placebo-treated group
from day 2 onward over the entire treatment period . The
mean change from baseline in the patients’ reflective daily
TSS over the 28-day treatment period, that was the
primary efficacy measure, was significantly greater forbilastine 20 mg and levocetirizine 5 mg treated groups
compared with placebo-treated group (P < 0.001 for bilas-
tine and levocetirizine vs placebo), but not significantly
different between the active treatment groups.
Cold urticaria is a quite uncommon form of inducible
urticaria, characterized by pruritic wheals and/or angio-
edema due to cutaneous mast cell activation and release
of pro-inflammatory mediators after cold exposure [30].
Reduction of symptoms in many patients with cold urti-
caria requires high dosing with antihistamines, up to four
times the daily recommended dose [31,32]. Krause et al.
assessed the effects of the standard 20 mg dose and up-
dosing to 40 and 80 mg of bilastine in reducing the symp-
toms of CU and inflammatory mediator release following
cold challenge in a randomized, crossover, double-blind,
placebo-controlled 12-week study [33]. In this study pa-
tients suffering from cold urticaria, confirmed by a spe-
cific provocation test, received placebo, 20, 40 or 80 mg
of bilastine daily each for 7 days with 14-day washout
periods. Bilastine was effective already at routine doses:
in patients receiving 20 mg, the critical temperature
threshold (CCT, the highest temperature that produces
a positive wheal response) was significantly different
from placebo (the median CCT value was 6°C in bilastine
group and 18°C in placebo group), P < 0.0001), as well
as the number of patients that became symptom free
(P = 0.044). The up-dosing was beneficial, since the me-
dian CTT with bilastine 80 mg was significantly lower
than that of 20 mg (P = 0.003) and 40 mg (P = 0.04). More-
over, inflammatory mediators were significantly reduce by
bilastine 80 mg.
Safety of bilastine
Tolerability data from the four phase III trials of 2–4
weeks duration are summarized in table 2. In these stud-
ies, bilastine was well tolerated and the majority of the




Disease AEs in bilastine-
treated group






Bachert C et a. [23] 721 SAR Any 28.3%
14 days Headache 12.0%
Somnolence 3.9%
Fatigue 2.6%




Zuberbiert T et al. [29] 525 CIU Any 30.1%
28 days Headache 12.1%
Somnolence 5.8%
Fatigue 2.9%
SAR: seasonal allergic rhinitis; PAR: persistent allergic rhinitis, CIU: chronic
idiopatic urticarial, AEs: adverse event.
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while no serious adverse events or death were reported;
moreover, there were no clinically significant changes in
any laboratory tests, ECGs, heart rate, or systolic and
diastolic blood pressure, in patients treated with bilastine
20 mg. The most common adverse effects were headache,
somnolence and fatigue that were reported less frequently
than in patients receiving cetirizine at 10 mg once daily.
The frequency of these adverse effects in patients with
SAR were comparable with that of desloratadine. The first
generation antihistamines cross the blood–brain barrier
and bind the H1-receptors on postsynaptic neurons
membranes in the central nervous system, causing sedation
and impaired mental status, while the second-generation
antihistamines usually do not cross the blood–brain barrier
and have fewer sedative effects. Bilastine 20 mg histamine
H1-receptor occupancy had been evaluated by positron
emission tomography (PET) in healthy subjects, con-
firming that bilastine has objective and PET criteria to
be defined as a non-sedating antihistamine [34]. More-
over, bilastine demonstrated to produce only very little
or even no performance impairment. In a crossover,
randomized, double-blind, placebo-controlled study 20
healthy volunteers received repeated doses of bilastine
20, 40, or 80 mg and first generation antihistaminehydroxyzine 25 mg on 7 consecutive days [35]. Bilastine
in doses up to 40 mg did not produce psychomotor im-
pairment as compared with placebo, even if 40 mg pro-
duced subjective report of sedation, and an objective
impairment was only evident at bilastine doses of 80 mg.
Similarly, bilastine did not produce any driving impair-
ment after single and repeated doses up to 40 mg [36]. At
the therapeutic dose of 20 mg the concomitant adminis-
tration of bilastine and alcohol does not produce greater
central nervous system (CNS) depressant effects than al-
cohol alone, while objective impairment induced bilastine
80 mg + alcohol (0.8 g/Kg) was of similar magnitude to
that induced by hydroxyzine 25 mg + alcohol [37]. Also
cardiac safety was confirmed at therapeutic and supra-
therapeutic doses. Bilastine administration at 20 mg and
100 mg had no clinically significant impact on QTc.
Concomitant administration of ketoconazole and bilastine
20 mg induced a clinically relevant increase in QTc but
this result was most likely related to the cardiac effect of
ketoconazole [38]. Moreover, bilastine, at therapeutic and
supratherapeutic dosages (up to 100 mg), did not induce
any effects on T-wave morphology [39].Conclusions
Bilastine epitomizes the evolution of research on antihis-
tamines concerning both efficacy and safety [40]. In AR
treatment, its efficacy has been documented in several
large controlled clinical trials [26]. Bousquet et al. in 2012
reviewed the available literature and found that bilastine
20 mg once daily improved all nasal and ocular symptoms
of AR and improved quality of life, an important outcome
in allergic diseases. Therefore, the authors concluded that
bilastine meets current EAACI/ARIA criteria for medi-
cations used in the treatment of AR [41]. In a comparable
review of the medical literature on the effectiveness of
bilastine in urticarial syndromes, either spontaneous or
inducible, Jauregui et al. concluded that once-daily treat-
ment with bilastine 20 mg was effective in managing symp-
toms and improving patient’s quality of life in chronic
urticaria [42]. Concerning safety and tolerability, the
profile of bilastine is very similar to placebo in all Phase
I, II and III clinical trials. Differently from most antihis-
tamines, bilastine does not increase the CNS depressant
effect of lorazepam and, unlike other second-generation
antihistamines such as cetirizine, does not increase al-
cohol effects on the CNS [43]. The balance of efficacy
and safety of bilastine is particularly helpful when dosages
higher than standard are needed to control the symptoms.
This is of particular importance when the doses are much
higher, as frequently occurs in patients with urticaria,
where antihistamines doses up to four times the standard
dose are administered, patient safety being a key require-
ment when choosing a specific antihistamine [44].
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